-
13-01-2019, 03:01 PM
#201
Originally Posted by percy
You need to research the largest shareholder.[controlling interest].
It is a joint venture between Andrew Bagnell and Peter Merton,who look to have premptive rights on each other's shareholding.
Then you have to research who Peter Merton holds for.Himself or Zuelig?
Then look at what company Zuelig holds 40% of.
If you find it is Ebos then you are on the right track.
At this point in time you would most probably be right to think EBO already controls GXH,as well as being their major supplier.
My guess if Andrew Bagnell ever wants out, then EBO will take it over.
Otherwise, should EBO decide there are more benefits for them to have, they will make a takeover bid for GXH.
Note Zuelig representitive and EBO director Peter Williams is a GXH director.
Thanks for sharing Percy, great researching, really helpful info
-
14-02-2019, 10:41 AM
#202
https://www.nzherald.co.nz/business/...ectid=12202567
Hard to get excited about this stock with this kind of news!
-
14-02-2019, 12:34 PM
#203
Originally Posted by Balance
NZ Pharmacies quite inefficient compared to many other countries. Where else would they ask a customer during a quiet time to wait 15 min to dispense their prescription medicine?
About time competitors moving in and creating a bit of excitement ...
----
"Prediction is very difficult, especially about the future" (Niels Bohr)
-
20-03-2019, 11:52 AM
#204
more big competition
more competition with the arrival of cut-price operator Bargain Chemist
https://www.stuff.co.nz/business/111308458/cut-price-bargain-chemist-moves-into-central-wellington
one step ahead of the herd
-
03-05-2019, 01:32 PM
#205
Originally Posted by bull....
more big competition
more competition with the arrival of cut-price operator Bargain Chemist
https://www.stuff.co.nz/business/111308458/cut-price-bargain-chemist-moves-into-central-wellington
Good points. GXH has some strategic advantages with their acquisition of general practises, real estate and locations.
Feel it is currently relatively undervalued yet there is additional pressure
The company is proactive and needs to keep up with the competition or outperform in service and convenience.
A fast growing market with a bigger population base and more and more out of the box demand for personally solvable health issues.
Had myself my first over 100% RIO with this one some years ago. Was a great performer. Feel that cycle is coming close to potential again.
-
03-05-2019, 01:34 PM
#206
Good divi stock at this price with a big upswing potential in share price increase.
Disc. Hold small parcel
-
20-05-2019, 11:06 AM
#207
Hmm - don't follow them that close, but why would the appointment of an interim CFO be marked as "price sensitive"?
https://www.nzx.com/announcements/334716
This guy that good - or that bad? He seems to have a history with GFX, which probably is good. However - just wondering - given he worked as well with Evolve Education, maybe he is deemed as too experienced in processing red numbers?
Last edited by BlackPeter; 20-05-2019 at 11:07 AM.
----
"Prediction is very difficult, especially about the future" (Niels Bohr)
-
28-05-2019, 03:35 PM
#208
Originally Posted by BlackPeter
Hmm - don't follow them that close, but why would the appointment of an interim CFO be marked as "price sensitive"?
https://www.nzx.com/announcements/334716
This guy that good - or that bad? He seems to have a history with GFX, which probably is good. However - just wondering - given he worked as well with Evolve Education, maybe he is deemed as too experienced in processing red numbers?
Good point BP.
IMO it is showing credibility and ability to manage the current situation.
Some reporting due in the next week. Divi date Mid June. Paid towards end of June.
Let's hope there's some good news in there. Plenty of scope for pharmacy and medical. Online store and home delivery options.
Disc. Holding small parcel. 👌
-
06-06-2019, 03:43 PM
#209
GXH overview NZX
Company info
Spike in price probably attributed to results and pre divi due 19 June
https://www.nzx.com/companies/GXH/analysis
👌💛
-
27-06-2019, 03:22 PM
#210
GXH Annual Report Out.
Result summary
• Revenue of $567m (+5.6%)
• EBITDA at $36.9m (+2.3%)
• Operating Profit $29.4m (-2.2%)
• Net Profit after Tax Attributable to the Parent Shareholders
of $16.1m (+3.2%)
• Pharmacy Revenue flat at $340m, Operating Profit down 5.5% at $27.3m
on the back of a record low cold and flu winter season and a decline in
gross margin as the company responded to competitive pressures
• Medical performed strongly with Revenue up 33.8% and Operating
Profit up 20.4% to $4.4m driven by an increase in enrolled patient
numbers from organic growth and selective acquisitions
• Community Health Revenue up 9.3% but Operating Profit $0.1m (down
$1.1m) as the division continues to struggle with under-funding from
various legislative changes
• Operating Cash Flow $29.5m (down $3.7m)
• Net Debt $32.5m (reduction of $6.0m)
Long term I believe this business has many more opportunities for growth. I am in favour of their direction with medical centre operations. Aware the pharmacy side is taking a slower growth path due to competition, yet they could grow in online sales themselves if they were to increase their focus in this area.
Reasonable divi 👌
Last edited by Food4Thought; 27-06-2019 at 06:10 PM.
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks